IRIS Institutional Research Information System - OPENBS Open Archive UniBS

POLVERELLI, NICOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.625
AS - Asia 4.101
EU - Europa 2.550
SA - Sud America 895
AF - Africa 106
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 2
Totale 13.287
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.455
SG - Singapore 1.664
CN - Cina 966
BR - Brasile 738
IT - Italia 700
HK - Hong Kong 503
DE - Germania 351
VN - Vietnam 314
FI - Finlandia 224
UA - Ucraina 221
FR - Francia 218
PL - Polonia 184
TR - Turchia 162
BD - Bangladesh 160
GB - Regno Unito 159
RU - Federazione Russa 158
IN - India 107
CA - Canada 84
IE - Irlanda 72
AR - Argentina 54
SE - Svezia 50
ZA - Sudafrica 48
MX - Messico 44
CZ - Repubblica Ceca 40
NL - Olanda 40
IQ - Iraq 39
JP - Giappone 35
ES - Italia 27
AT - Austria 26
EC - Ecuador 20
CO - Colombia 19
BE - Belgio 17
VE - Venezuela 17
JO - Giordania 16
ID - Indonesia 14
PY - Paraguay 14
PE - Perù 13
MA - Marocco 12
UZ - Uzbekistan 11
SA - Arabia Saudita 10
TH - Thailandia 10
AE - Emirati Arabi Uniti 9
EG - Egitto 9
PH - Filippine 9
ET - Etiopia 8
IL - Israele 8
JM - Giamaica 8
MY - Malesia 8
PK - Pakistan 8
PT - Portogallo 8
TN - Tunisia 8
AU - Australia 7
AZ - Azerbaigian 7
CL - Cile 7
CR - Costa Rica 7
GR - Grecia 7
LT - Lituania 7
PA - Panama 7
UY - Uruguay 7
BO - Bolivia 6
DZ - Algeria 6
HN - Honduras 6
KE - Kenya 6
KG - Kirghizistan 6
BG - Bulgaria 5
IR - Iran 5
LV - Lettonia 5
OM - Oman 5
PS - Palestinian Territory 5
LK - Sri Lanka 4
MD - Moldavia 4
TT - Trinidad e Tobago 4
CH - Svizzera 3
HU - Ungheria 3
SN - Senegal 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
AL - Albania 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
EE - Estonia 2
EU - Europa 2
GA - Gabon 2
GT - Guatemala 2
HR - Croazia 2
IM - Isola di Man 2
KR - Corea 2
KZ - Kazakistan 2
NI - Nicaragua 2
NP - Nepal 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
AM - Armenia 1
AO - Angola 1
BH - Bahrain 1
BZ - Belize 1
CY - Cipro 1
Totale 13.278
Salva come PNG Salva come JPEG
Città #
Singapore 895
Ashburn 606
Hong Kong 501
San Jose 454
Fairfield 377
Beijing 284
New York 253
The Dalles 227
Chandler 195
Woodbridge 194
Warsaw 172
Seattle 171
Dallas 165
Jacksonville 161
Helsinki 160
Munich 160
Los Angeles 159
Wilmington 145
Cambridge 138
Brescia 134
Houston 127
Lauterbourg 123
Ann Arbor 121
Istanbul 116
Princeton 115
Ho Chi Minh City 97
Des Moines 79
São Paulo 79
Hanoi 70
Dublin 69
Shanghai 66
Chicago 62
Boardman 61
Moscow 61
San Francisco 61
Santa Clara 59
Buffalo 57
Redondo Beach 57
Turku 47
Milan 46
Orem 46
Romola 41
Council Bluffs 38
London 36
Johannesburg 32
Tokyo 32
Brno 30
Rome 30
Frankfurt am Main 27
Montreal 27
Nuremberg 27
Brooklyn 25
Atlanta 24
Denver 24
Belo Horizonte 21
Toronto 21
Charlotte 20
Nanjing 20
Rio de Janeiro 20
Pune 19
San Diego 19
Boston 18
Chennai 18
Manchester 18
Phoenix 18
Stockholm 18
Amsterdam 17
Brussels 17
Da Nang 17
Jinan 17
Amman 16
Haiphong 16
Guangzhou 15
Brasília 14
Tianjin 14
Baghdad 13
Dearborn 13
Kyiv 13
Paris 13
Barlassina 12
Biên Hòa 12
Curitiba 12
Florence 12
Lappeenranta 12
Mexico City 12
Mumbai 12
Poplar 12
Shenyang 11
Turin 11
Changsha 10
Genoa 10
Tashkent 10
Verona 10
Wroclaw 10
Ankara 9
Bologna 9
Bosio 9
Dhaka 9
Hangzhou 9
Hải Dương 9
Totale 8.210
Salva come PNG Salva come JPEG
Nome #
BACTERIAL BLOOD STREAM INFECTIONS NEGATIVELY IMPACT ON OUTCOME OF PATIENTS TREATED WITH ALLOGENEIC STEM CELL TRANSPLANTATION: 6 YEARS SINGLE-CENTRE EXPERIENCE 295
Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia 210
Comparative study on ATG-thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years 198
Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF) 186
Advances in CMV Management: A Single Center Real-Life Experience 177
Multidimensional Geriatric Assessment for Elderly Patients (≥60 years) Submitted for Allogeneic Stem Cell Transplantation. a French (Paris) - Italian (Brescia) 10-Years Experience on 228 Patients 170
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 169
Clinical Care of Hematological Patients in a Bone Marrow Transplant Unit: Do Human Resources Influence Infection Incidence? 165
Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms 165
CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS 163
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 160
High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review 158
Identification of a Novel Mutation Predisposing to Familial AML and MDS Syndrome By a NGS Approach 157
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial 156
RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients? 154
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 150
First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response 150
Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner? 148
CT-290: Clinical Frailty Scale as a Novel Tool to Evaluate Patients’ Eligibility for Allogeneic Stem Cell Transplant: A Single-Center Experience on 234 Patients >50 Years Old 146
ANTI-CMV Immunoglobulins in Association with ANTI-CMV Drugs in Patients with Hematological Malignancies Submitted to Allogeneic STEM CELL Transplantation: A MULTI-Center Retrospective Experience 144
Digital PCR (Dpcr) a Step Forward to Detection and Quantification of Minimal Residual Disease (MRD) in Ph+/BCR-ABL1 Chronic Myeloid Leukemia (CML) 141
Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients 140
Comparative Study on Fresenius-ATG Versus Thymoglobuline-ATG for the Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation from Matched Unrelated Donor: A Single Center Experience on 76 Patients 138
Bone marrow CD34+ molecular chimerism as an early predictor of relapse after allogeneic stem cell transplantation in patients with acute myeloid leukemia 136
ETV6: A Candidate Gene for Predisposition to “Blend Pedigrees”? A Case Report from the NEXT-Famly Clinical Trial 135
Successful hematopoietic stem cell transplantation for complete CTLA-4 haploinsufficiency due to a de novo monoallelic 2q33.2-2q33.3 deletion 135
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations 134
ANTI-CMV IMMUNOGLOBULINS IN ASSOCIATION WITH ANTI-CMV DRUGS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES SUBMITTED TO ALLOGENEIC STEM CELL TRANSPLANTATION: A MULTI-CENTRE RETROSPECTIVE EXPERIENCE 131
Allogeneic transplantation for patient with myelodisplastic sindromes: a single centre experience 131
IN VIVO STUDY (MYCEC0617) OF CD34+-HSC AND CEC MUTATIONAL PROFILE FOR INVESTIGATING CELL ORIGIN AND PATHOGENESIS OF PRIMARY MYELOFIBROSIS (PMF) 131
PB2209: HIGH RISK MYELODYSPLASTIC SYNDROME DEVELOPING IN A PATIENT AFTER CHIMERIC ANTIGEN RECEPTOR (CAR) T- CELL THERAPY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA 130
Case Report: Late Onset of Myelodysplastic Syndrome From Donor Progenitor Cells After Allogeneic Stem Cell Transplantation. Which Lessons Can We Draw From the Reported Case? 130
P1450: AUTOLOGOUS STEM CELL TRANSPLANTATION INDUCES HIGHER LEVEL OF EXHAUSTED T-CELLS IN DLBCL PATIENTS BEFORE LEUKAPHERESIS FOR CAR-T CELL THERAPY 129
DIGITAL PCR IN PH plus CHRONIC MYELOID LEUKEMIA PATIENTS FOR RECOGNITION OF "STABLE" DEEP MOLECULAR RESPONSE AND IDENTIFICATION OF BEST CANDIDATES TO TKI DISCONTINUATION 128
Sequential monitoring of lymphocyte subsets and of T-and-B cell neogenesis indexes to identify time-varying immunologic profiles in relation to graft-versus-host disease and relapse after allogeneic stem cell transplantation 128
Safety and Efficacy of ATG-based GvHD prophylaxis in allogeneic stem cell transplantation for acute leukemia and myelodysplastic syndrome: a single center experience 127
Pre-Emptive Donor Lymphocyte Infusion As Optimal Treatment for Relapsed Acute Myeloid Leukemias and Myelodysplastic Syndromes Following Allogeneic Stem Cell Transplantation: Insights from a French-Italian Study on 134 Patients 126
Liposomal doxorubicin for the treatment of iatrogenic kaposi sarcoma following hematopoietic stem cell transplantation 126
3-YEARS and Beyond Study Completion Results of the Otpkima Randomized Clinical Trial in Elderly CML Patients 125
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 125
Autologous Stem Cell Transplantation before Lymphocyte Apheresis for CAR-T Cells Therapy Negatively Impacts on T-Cells Fitness and NK Cell Levels in DLBCL Patients 124
OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY 123
Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey) 122
Feasibility of Leukemia-Derived Exosome Enrichment and Co-isolated dsDNA Sequencing in Acute Myeloid Leukemia Patients: A Proof of Concept for New Leukemia Biomarkers Detection 121
Nutritional intervention with TGF-beta enriched food for special medical purposes (TGF-FSMP) is associated with a reduction of malnutrition, acute GVHD, pneumonia and may improve overall survival in patients undergoing allogeneic hematopoietic stem transplantation 121
Comparative monitoring of deep molecular response (DMR) by RT-quantitative (RT-qPCR) and digital PCR (dPCR) in Ph+ Chronic Myeloid Leukemia (CML) patients treated with TKIs for recognition of stable deep molecular response (DMR) and identification of best candidates to TKIs treatment discontinuation. 121
EXTRACORPOREAL PHOTOPHERESIS FOR THE TREATEMENT OF ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE: A RETROSPECTIVE MULTICENTRIC ANALYSIS ON 94 PATIENTS. 118
A Systematic Review of the Literature and Perspectives on the Role of Biomarkers in the Management of Malnutrition After Allogeneic Hematopoietic Stem Cell Transplantation 118
Post Induction and Post Consolidation Measurable/Minimal Residual Disease Predict Relapse in NPM-1 Positive AML. Outcome of Treatment Relapse. a Single Center Experience 117
EXTRACORPOREAL PHOTOPHERESIS (ECP) FOR TREATEMENT OF ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE: AN ITALIAN MULTICENTRIC RETROSPECTIVE ANALYSIS ON 94 PATIENTS ON BEHALF OF THE GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO (GITMO) 115
PS1540 MULTIPARAMETRIC PREDICTIVE SCORE FOR GRAFT VERSUS HOST DISEASE (GVHD) IN PATIENTS SUBMITTED TO ALLOGENEIC STEM CELLS TRANSPLANTATION (SCT) 113
Results of an Innovative Program for Surveillance, Prophylaxis, and Treatment of Infectious Complications Following Allogeneic Stem Cell Transplantation in Hematological Malignancies (BATMO Protocol) 111
Timely Leukapheresis May Interfere with the “Fitness” of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients 110
Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis 110
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 108
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 108
Potentiality of Bone Marrow-Derived Mesenchymal Stromal Cells (BM-MSCs) to Differentiate into the Osteogenic Lineage in in Vitro Model of Tissue Regeneration 107
Correlation between BCR::ABL1 Transcript LEVEL in Circulating Extracellular Vesicles and BOTH the Molecular Response and the Ongoing Therapy: A Study on Adult CML Patients 107
Incidence and Outcome of Bacterial Blood Stream Infections in Allotransplanted Patients: Rethinking the Role of Fluoroquinolone Prophylaxis 104
Severe Acute Respiratory Syndrome Coronavirus-2 Pandemia: Facts and Perspectives in a Bone Marrow Transplant Unit 104
Malnutrition Prevention after Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT): A Prospective Explorative Interventional Study with an Oral Polymeric Formulation Enriched with Transforming Growth Factor Beta 2 (TGF-β2) 102
Evaluation of Circulating Endothelial Cells (CECs) As Marker of Endothelial Damage in Allo-Transplanted Patients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS): The Cecinvod Study 102
Exosomes in Chronic Myeloid Leukemia: Are We Reading a New Reliable Message? 102
dsDNA from extracellular vesicles (EVs) in adult AML 102
Successful CAR-T cell therapy in a refractory MCL patient with bacterial, fungal and COVID-19 infection: a case report 100
Favourable/Intermediate ELN-Risk Acute Myeloid Leukemia to Transplant or Not to Transplant First-Line? 100
Outcome of Patients With Acute Myeloid Leukemias or Myelodysplastic Syndromes After Relapsing From Allogeneic Stem Cell Transplantation: The GITMO AML/MDS‐Relapse Registry Study 98
PF404 TUMOR-DERIVED EXOSOMES MAY BE USED AS NEW INFORMATIVE TOOL FOR THE DETECTION OF BONE MARROW RESIDUAL CML LEUKEMIC CELLS ACTIVITY 98
CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation 97
PF688 JAK2 ALLELIC RATIO IMPACTS ON VASCULAR EVENT IN MYELOFIBROSIS BY INCREASING THE RISK OF THROMBOSIS. A SINGLE CENTER EXPERIENCE ON 150 PATIENTS 94
How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation 94
PB1959: BCR::ABL1 TRANSCRIPT IN SMALL EXTRACELLULAR VESICLES ISOLATED IN ADULT CHRONIC MYELOID LEUKEMIA PATIENTS CORRELATES WITH MOLECULAR RESPONSE LEVEL AND THE ONGOING THERAPY 94
Donor Lymphocyte Infusion in the Treatment of Post-Transplant Relapse of Acute Myeloid Leukemias and Myelodysplastic Syndromes Significantly Improves Overall Survival: A French–Italian Experience of 134 Patients 93
Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT) 93
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study 88
Minimal residual disease monitoring in acute myeloid leukaemia: are we ready to move from bone marrow to peripheral blood? 86
Association of essential thrombocythemia and non-Hodgkin lymphoma: A single-centre experience 80
S882 OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY 80
Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party 78
Correction: CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation (Bone Marrow Transplantation, (2023), 10.1038/s41409-023-02124-y) 78
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera 76
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 76
Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study 74
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: Possible role of MPL polymorphisms 74
MALNUTRITION AND GVHD IN ALLOGENIC BONE MARROW TRANSPLANTATION: A PROSPECTIVE STUDY 73
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 69
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis 69
Long-term follow-up of essential thrombocythemia in young adults: Treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients 68
Splenectomy as a curative treatment for immune thrombocytopenia: A retrospective analysis of 233 patients with a minimum follow up of 10 years 67
A case report of acute myeloid leukemia and neurofibromatosis 1 67
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 64
Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT 64
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 63
Bleeding in essential thrombocythaemia: A retrospective analysis on 565 patients 63
Digital PCR as a New Method for Minimal Residual Disease Monitoring and Treatment Free Remission Management in Chronic Myeloid Leukemia Patients: Is It Reliable? 62
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT 62
Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis 60
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis 60
Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease 60
Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study 60
Totale 11.519
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.753
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.753
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022559 48 33 18 42 18 45 27 49 30 87 33 129
2022/2023683 79 19 30 52 55 136 3 129 82 17 43 38
2023/20241.196 51 26 96 62 72 221 50 46 287 14 17 254
2024/20252.877 39 56 82 334 291 240 175 116 399 236 522 387
2025/20266.025 508 618 495 919 566 404 830 271 380 578 243 213
2026/202742 42 0 0 0 0 0 0 0 0 0 0 0
Totale 13.484